These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 11104741)

  • 1. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
    Rothman RB; Baumann MH; Savage JE; Rauser L; McBride A; Hufeisen SJ; Roth BL
    Circulation; 2000 Dec; 102(23):2836-41. PubMed ID: 11104741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
    Fitzgerald LW; Burn TC; Brown BS; Patterson JP; Corjay MH; Valentine PA; Sun JH; Link JR; Abbaszade I; Hollis JM; Largent BL; Hartig PR; Hollis GF; Meunier PC; Robichaud AJ; Robertson DW
    Mol Pharmacol; 2000 Jan; 57(1):75-81. PubMed ID: 10617681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonergic drugs and valvular heart disease.
    Rothman RB; Baumann MH
    Expert Opin Drug Saf; 2009 May; 8(3):317-29. PubMed ID: 19505264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.
    Setola V; Hufeisen SJ; Grande-Allen KJ; Vesely I; Glennon RA; Blough B; Rothman RB; Roth BL
    Mol Pharmacol; 2003 Jun; 63(6):1223-9. PubMed ID: 12761331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects.
    Rothman RB; Baumann MH
    Pharmacol Biochem Behav; 2002 Apr; 71(4):825-36. PubMed ID: 11888573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors.
    Vickers SP; Dourish CT; Kennett GA
    Neuropharmacology; 2001 Aug; 41(2):200-9. PubMed ID: 11489456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fenfluramine metabolite (+)-norfenfluramine is vasoactive.
    Ni W; Li MW; Thakali K; Fink GD; Watts SW
    J Pharmacol Exp Ther; 2004 May; 309(2):845-52. PubMed ID: 14752059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux.
    Johnson GJ; Leis LA; Dunlop PC; Weir EK
    J Thromb Haemost; 2003 Dec; 1(12):2663-8. PubMed ID: 14675103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor.
    Setola V; Dukat M; Glennon RA; Roth BL
    Mol Pharmacol; 2005 Jul; 68(1):20-33. PubMed ID: 15831837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonergic facilitation of acetylcholine release in vivo from rat dorsal hippocampus via serotonin 5-HT3 receptors.
    Consolo S; Bertorelli R; Russi G; Zambelli M; Ladinsky H
    J Neurochem; 1994 Jun; 62(6):2254-61. PubMed ID: 8189232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms.
    Caccia S; Anelli M; Fracasso C; Frittoli E; Giorcelli P; Gobbi M; Taddei C; Garattini S; Mennini T
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Mar; 347(3):306-12. PubMed ID: 8479546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release.
    Callaway CW; Wing LL; Nichols DE; Geyer MA
    Psychopharmacology (Berl); 1993; 111(2):169-78. PubMed ID: 7870948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is receptor activation involved in the mechanism by which (+)-fenfluramine and (+)-norfenfluramine deplete 5-hydroxytryptamine in the rat brain?
    Invernizzi R; Kmieciak-Kolada K; Samanin R
    Br J Pharmacol; 1982 Mar; 75(3):525-30. PubMed ID: 6175368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine.
    Welch JT; Lim DS
    Bioorg Med Chem; 2007 Nov; 15(21):6659-66. PubMed ID: 17765553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic and adverse actions of serotonin transporter substrates.
    Rothman RB; Baumann MH
    Pharmacol Ther; 2002 Jul; 95(1):73-88. PubMed ID: 12163129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appetite suppressants, cardiac valve disease and combination pharmacotherapy.
    Rothman RB; Baumann MH
    Am J Ther; 2009; 16(4):354-64. PubMed ID: 19092640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity.
    Miller KJ
    Mol Interv; 2005 Oct; 5(5):282-91. PubMed ID: 16249524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. d-Fenfluramine and d-norfenfluramine hypophagias do not require increased hypothalamic 5-hydroxytryptamine release.
    Oluyomi AO; Gibson EL; Barnfield AM; Curzon G
    Eur J Pharmacol; 1994 Oct; 264(1):111-5. PubMed ID: 7828639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment.
    Huang XP; Setola V; Yadav PN; Allen JA; Rogan SC; Hanson BJ; Revankar C; Robers M; Doucette C; Roth BL
    Mol Pharmacol; 2009 Oct; 76(4):710-22. PubMed ID: 19570945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters.
    Rothman RB; Clark RD; Partilla JS; Baumann MH
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1191-9. PubMed ID: 12649307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.